On July 24, CSPC Pharmaceutical Group (1093.HK) announced that its independently developed second-generation antipsychotic long-acting injection, paliperidone palmitate injection (specifications include: (1) 0.75ml:75mg; (2) 1.0ml:100mg; (3) 1.5ml:150mg (calculated as C 23 H 27 FN 4 O 3 ) (hereinafter referred to as "the product"), has been approved for marketing by the National Medical Products Administration of the People's Republic of China and is suitable for the treatment of acute and maintenance phases of schizophrenia.

Compared to traditional antipsychotic drugs, this product only needs to be administered once a month, and it takes effect quickly after administration, requiring no oral medication supplementation. It can be used to treat patients in the acute phase. At the same time, monthly administration significantly improves patient medication adherence, avoids missed doses, and effectively reduces the relapse rate and readmission rate.
This product is listed as a recommended medication in authoritative domestic and international treatment guidelines such as the "Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition)". It is the preferred treatment for schizophrenia patients with poor adherence and high risk of relapse, and has high clinical and pharmacoeconomic value.
The approval of this product will further enrich the Group's product pipeline in the field of neuropsychiatry. The Group will continue to dedicate itself to developing more drugs with high clinical value, providing better treatment options for patients.

https://bydrug.pharmcube.com/news/detail/7adc37c018403ac1cf7ef82544f88eb9